Tag Archives: What is Cdiff?

Summit Therapeutics plc Phase 2 Clinical Trial Ridinilazole In Development For the Treatment of C. difficile Infection

Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health

July 13, 2020 – Summit Therapeutics plc announced the publication of data from the Phase 2 clinical trial of the company’s precision antibiotic, ridinilazole, in development for the treatment of C. difficile infection (‘CDI’) in the American Journal of Physiology – Gastrointestinal and Liver Physiology. The data published in collaboration with researchers at Tufts University and Tufts Medical Center demonstrated that ridinilazole’s microbiome preservation resulted in a gut environment expected to inhibit the growth of C. difficile. In contrast, vancomycin treatment resulted in a gut environment that may more highly favor the growth of C. difficile. The difference in gut environment could explain the approximately 60% relative reduction in recurrence observed in patients treated with ridinilazole over vancomycin in the Phase 2 trial.

“This is the first scientific article ever to show the effect of antibiotics treating CDI on the bile acid composition in the human gut. In addition, CoDIFy is the first clinical study to highlight the differential effects of antibiotics on bile acids, which are known to create environments that can either promote or protect against CDI,” said Dr. Ventzislav Stefanov, Executive Vice President and President of Discuva. “The protective gut environment observed after ridinilazole treatment, compared to vancomycin, provides a strong rationale for the higher sustained clinical response observed in patients taking ridinilazole in the CoDIFy clinical trial.”

The Phase 2 clinical trial enrolled 100 patients, half of whom received ridinilazole and the other half vancomycin. The publication, “Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids,” was authored by X. Qian, K. Yanagi, A. Kane, N. Alden, M. Lei, D. Snydman, R. Vickers, K. Lee and C. Thorpe. In the published data, there was a higher ratio of pro-C. difficile to anti C.-difficile bile acids at the start of treatment for both ridinilazole- and vancomycin-treated patients. This was expected, as patients who get CDI have perturbed microbiomes. However, during treatment, patients treated with vancomycin showed a further decrease in anti-C. difficile bile acids and had stools dominated by pro-C. difficile bile acids. In contrast, this did not occur in ridinilazole-treated patients. By the end of the study period, ridinilazole-treated patients’ bile acid ratios trended towards a healthy, non-CDI state. These results support the data from the Phase 2 clinical trial, in which patients receiving ridinilazole showed a statistically significant improvement in sustained clinical responses.

SOURCE: https://seekingalpha.com/pr/17929120-summit-announces-publication-of-phase-2-clinical-analyses-of-gut-microbiome-health

The 4th Annual Global C. diff. Awareness 2K Walks Go Virtual on September 11 and 12

The 4th Annual Global C.diff. Awareness 2K Walks Will Now Be VIRTUAL!

                   Join Us On……………….

Friday, September 11th – UK

Dr. Clokie, UK Walk Event Coordinator, will be hosting the VIRTUAL Walk in Leicester on September 11th as the UK is also under strict guidelines to slow the spread of the COVID-19 virus. 

  • The Leicester VIRTUAL Walk Will Begin at 10:00 a.m. – 11:00 a.m. – UK

  • VIRTUAL Entertainment Will Begin at 10:00 a.m. UK For the Children!

Saturday, September 12th –  USA

  • The VIRTUAL Walks Will Begin at 9:00 a.m. through 12:00 p.m. EDT

  • VIRTUAL Entertainment Will Begin at 9:00 a.m. EDT For the Children!

All Registered Awareness Walkers Will Receive a T-Shirt, Giveaways, and More via: United States Postal Service To the Address Provided at the Time Of Registration.

To Learn More About the Global C. diff. Awareness Walk Event and How You Can Register, Please Click On the Green Button Below……………..

C Diff Foundation Members Are Here For YOU Especially During the Pandemic

To Our Dear Patients, Families, and Healthcare Professionals,

To say these times have been trying is a giant understatement. We hope that you and your families are staying safe during this period of self quarantine, social distancing and limiting your daily exposures to help flatten the curve of COVID-19.

If anything is to come of this, we hope that it will be the value of hand washing, which will in turn help to prevent the spread of Healthcare-associated infections (HAI’s).

COVID-19 is in the forefront and this pandemic has majorly changed our lives. We are living through this together while healthcare professionals, across the globe, are dedicated  in developing the best possible practices for infection prevention, treatments and safety in public health.  For up-to-date COVID-19 information, please visit the CDC website:  www.cdc.gov

Be rest assured that the C Diff Foundation members continue to work diligently to educate and advocate for C. diff.  Infection prevention,  treatments, clinical trials, diagnostics, environmental safety and support to help those diagnosed with, being treated for, and recovering from a
C. diff. Infection worldwide.

Should you find yourself needing assistance with C. diff. infection information and support, please do not hesitate to contact us. We are here for you, your families, friends and healthcare professionals to see you through, and beyond a C. diff. infection.

A huge thank you goes out from all of us here at the C Diff Foundation to the brave men and women on the front lines of this pandemic. Without you and your bravery,  we would be in a major state of disarray. Thank you for being a guiding light for us all worldwide.

Check in on your neighbors, friends and families to make sure that they are okay. Keep your spirits high and know that we will get through this together.

“None of us can do this alone ~ All of us can do this together.”

C Diff Foundation Members Are Here For YOU Even During the Pandemic

To Our Dear Patients, Families, and Healthcare Professionals,

To say these times have been trying is a giant understatement. We hope that you and your families are staying safe during this period of self quarantine, social distancing and limiting your daily exposures to help flatten the curve of COVID-19.

If anything is to come of this, we hope that it will be the value of hand washing, which will in turn help to prevent the spread of Healthcare-associated infections (HAI’s).

COVID-19 is in the forefront and this pandemic has majorly changed our lives. We are living through this together while healthcare professionals, across the globe, are dedicated  in developing the best possible practices for infection prevention, treatments and safety in public health.  For up-to-date COVID-19 information, please visit the CDC website:  www.cdc.gov

Be rest assured that the C Diff Foundation members continue to work diligently to educate and advocate for C. diff.  Infection prevention,  treatments, clinical trials, diagnostics, environmental safety and support to help those diagnosed with, being treated for, and recovering from a
C. diff. Infection worldwide.

Should you find yourself needing assistance with C. diff. infection information and support, please do not hesitate to contact us. We are here for you, your families, friends and healthcare professionals to see you through, and beyond a C. diff. infection.

A huge thank you goes out from all of us here at the C Diff Foundation to the brave men and women on the front lines of this pandemic. Without you and your bravery,  we would be in a major state of disarray. Thank you for being a guiding light for us all worldwide.

Check in on your neighbors, friends and families to make sure that they are okay. Keep your spirits high and know that we will get through this together.

“None of us can do this alone ~ All of us can do this together.”

C Diff Foundation with Leading Gastroenterologist’s Oneto and Feuerstadt Announce November Clinic Dedicated for C.difficile

C Diff Foundation ( https://cdifffoundation.org/)  is a one hundred percent volunteer, world-renowned 501(c)(3) not-for-profit organization and has announced that the Foundation will offer a November clinic sponsored by the C Diff Foundation and dedicated to patients diagnosed and recovering from a C. difficile infection (CDI).

The November 19th C Diff Foundation Clinic will be hosted by Concorde Gastroenterology at their  233 Broadway Suite 840,  New York, NY 10279 office.
The clinic will hold office hours from 10:00 a.m. until  4:00 p.m. ET
With Doctor’s Caterina Oneto, MD and  Paul Feuerstadt, MD

Please call +1 212 889 5544 Ext 199
To schedule an appointment.

The August clinic received an overwhelming response from patients in various stages of recovery, including 15 individuals already scheduled with multiple spots planned for patients with recently diagnosed infection or those who have had multiple episodes and need further guidance and management.

Dr. Oneto said, “Through this clinic, we will provide access to high-level care to a number of new consults, as well as existing patients, who are recovering from the infection. It is my pleasure to partner with the C Diff Foundation and lend my expertise to the management and hopefully, eradication of this debilitating disease.”

“We are delighted with the immediate and overwhelming response from the patient community. It is a testament to the needs of those suffering from this infection. With this clinic, we hope to bring awareness, education and more importantly, cutting edge treatment to the general public,” stated Dr. Feuerstadt.

There are plans for additional clinic dates in 2020  in Florida, New York, Connecticut, Illinois, and Minnesota.

“The clinics demonstrate Doctor Oneto and Feuerstadt’s commitment over the years raising
C. diff. awareness while providing management of those suffering with
a C. diff. infection. Patients who might not otherwise be able to gain access to providers sub-specializing and caring for those with this infection will have this opportunity available.  Doctor’s Oneto and Feuerstadt’s dedication resonates within the C. diff. community and we are grateful for their participation and support.” stated Nancy Caralla, Founding President and Executive Director of the C Diff Foundation.

About C Diff Foundation

C Diff Foundation’s mission is dedicated to reaching out to communities from villages to cities, to medical practitioners, medical students, C. diff. survivors, caregivers, and the patients combating a C. difficile infection (CDI) while providing the general public important information on prevention, treatments available, clinical trials in progress, nutrition, diagnostics, and EPA registered products available for environmental safety worldwide.

About Caterina Oneto, MD

Dr. Caterina Oneto, MD is a Gastroenterologist in private practice in New York and is affiliated with NYU Langone. She completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. Dr. Oneto is the Co-Director of Clinical trials at Concorde Medical Group. Her main focus is Irritable Bowel Disease (IBD),

About Paul Feuerstadt, MD

His areas of interest Clostridioides difficile infection (CDI) and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters, and online modules. Another passion of Dr. Feuerstadt is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full-time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York-Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

Clostridioides difficile infections (AKA C. diff., C.difficile, CDI) and Microbiome modification.
Dr Oneto is also Co-Director of the C.diff. Community Global Support program offered by the
C Diff Foundation.  Dr. Oneto appears regularly on Doctor Radio on Sirius Xm
and C. diff. Spores and More Radio (cdiffradio.com).

About C.difficile

It is the most common Healthcare-associated infection affecting an estimated 450,000 people annually in the United States alone with ~28,000 deaths from complications of this infection. This infection accounts for ~16% of all healthcare-associated infections.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released on February 25, 2015, by the Centers for Disease Control and Prevention (CDC).

**Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections (CDI), making C. difficile a very important cause of infectious disease death in the United States alone. More than 80 percent of the deaths associated with C. difficile occurred among Americans aged 65 years or older. C. difficile causes an inflammation of the colon and deadly diarrhea.